MHRA (UK) has approved the subcutaneous version of Ocrevus to treat patients with relapsing and primary progressive multiple sclerosis – Roche

The United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Roche’s subcutaneous version of Ocrevus (ocrelizumab subcutaneous ) to treat patients with relapsing and primary progressive multiple sclerosis.

Previously approved in the U.K. as an infusion, the drug can now be given as a subcutaneous injection by a doctor or nurse every six months. In a randomized study of 236 patients, patients who received a single dose of the injected drug had similar levels of medicine in the blood as those who received two infusions. Elsewhere, regulators in Europe granted subcutaneous Ocrevus an approval last month.